title: Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective.
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Charokopou
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: H
authors.initials: H
authors.lastname: Vioix
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: B G
authors.initials: BG
authors.lastname: Verheggen
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: D
authors.initials: D
authors.lastname: Maddocks
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: T
authors.initials: T
authors.lastname: Bratt
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: D
authors.initials: D
authors.lastname: Franks